Navigation Links
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Date:5/6/2009

Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting

SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of serious bacterial infections, announced today that the results of multiple studies from its lead program, torezolid (TR-701), will be presented in an oral session and six poster presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland May 16-19. Torezolid is a novel antibiotic that recently completed Phase 2 clinical development with potent activity against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

The presentations are as follows:

Saturday, May 16th

Oral Presentation - Lecture Hall 3a (14:54 - 15:06)

  • O28: In vivo pharmacodynamics of TR-701, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains; A. Louie, C. Fregeau, W. Liu, H. Conde, R. Kulawy, G. Drusano

Sunday, May 17th

Poster Presentations - New antimicrobials against Gram-positives (13:30 - 14:30)

  • P 1091: Effects of food on the pharmacokinetics of TR-701, a novel oxazolidinone prodrug antibiotic, in healthy adult subjects; KA. Munoz, P. Bien, P. Prokocimer, M. Berry, C. R. Bethune
  • P 1092: TR-700, a novel methyltetrazolyl-oxazolidinone, accumulates extensively within human macrophages cells and shows activity towards intraphagocytic linezolid-sensitive and linezolid-resistant S. aureus; S. Lemaire, K. Kosowska-Shick, P. Appelbaum, F. Van Bambeke, P. Tulkens
  • P 1090: The safety of single ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1089: The safety of multiple ascending oral doses of TR-701, a novel oxazolidinone prodrug antibiotic; P. Bien, P. Prokocimer, KA. Munoz, J. Bohn
  • P 1103: Characterization of resistance following serial passage of Staphylococcus aureus in the presence of the novel oxazolidinone TR-700 and linezolid; J. Locke, K. Shaw
  • P 1104: Characterization of the novel oxazolidinone TR-700 and linezolid spontaneous mutation frequencies and resistance mechanisms in Staphylococcus aureus; J. Locke, K. Shaw

Copies of these posters will be available on the Trius Web site following the ECCMID meeting: http://www.triusrx.com/posters.php.

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by drug-resistant pathogens. The company's lead drug candidate, torezolid, is a second generation oral and IV oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R), the only marketed antibacterial drug of the oxazolidinone class. Trius has recently completed Phase 2 testing of torezolid in a U.S. based multi-center trial. Trius' pipeline includes two preclinical programs with lead candidates being developed to treat serious infections caused by Gram-negative bacterial pathogens. For more information, visit www.triusrx.com.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
2. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. PacificGMP Completes GMP Product Fill for Trius Therapeutics
5. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
6. Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders
7. Sirion Therapeutics Announces Clinical Data Presentations at the 2009 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
8. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
9. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
10. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
11. Vantia Therapeutics Pipeline Continues to Mature
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... May 8, 2017 MACRA replaces the ... fee for service reimbursement. Black Book Research crowdsource-surveyed 8,845 ... 1.       The Market for MIPS Compliance Technology is ... physician practices with 3 or more clinicians seek to ... Q4. "Given the magnitude of the changes, the hunt ...
(Date:5/4/2017)... May 4, 2017  Fortuna Fix Inc. (" Fortuna ... the first to eliminate the need for embryonic and fetal ... treat neurodegenerative diseases. Fortuna announced today ... Michael Fehlings , MD, PhD; Father Kevin FitzGerald ... MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)...  A new tight-tolerance microextrusion medical tubing product ... is being launched by Natvar, a Tekni-Plex company. ... recent years to service a wide variety of ... expensive materials such as glass and fluoropolymers have ... their ability to consistently hold tolerances. This is ...
Breaking Medicine Technology:
(Date:5/27/2017)... California (PRWEB) , ... May 26, 2017 , ... A ... citizens who visit a doctor for colds or respiratory issues that are not responsive ... excessive time pressure on doctors may be largely responsible for the problem both in ...
(Date:5/27/2017)... CA (PRWEB) , ... May 27, 2017 , ... Most ... for concern, but a new study from the Osteoarthritis Initiative shows that ... developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity to treat ...
(Date:5/26/2017)... ... May 26, 2017 , ... The Radiology ... to focus on current legislative activity and the latest regulatory concerns impacting RBMA ... Sunday, Sept. 10, and will continue through Monday, Sept. 11, at the Ritz-Carlton, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s ... sharing bold recipes for Memorial Day entertaining that are sure to satisfy your ... Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes are ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Yisrayl Hawkins, Pastor ... publication this week that is focusing on the Peace Agreements being discussed by President ... East sprint in a race to try to speed up peace talks in the ...
Breaking Medicine News(10 mins):